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“Night science, hesitates, stumbles, recoils, sweats, wakes with a start. 
Doubting everything, it is forever trying to find itself, question itself, pull 
itself back together. Night science is a sort of workshop of the possible where 
what will become the building material of science is worked out. Where 
phenomena are still mere solitary events with no link between them. Where 
thought makes its way along meandering paths and twisting lanes, most often 
leading nowhere. What guides the mind, then, is not logic but instinct, 
intuition. The need to understand.” 
 
 
François Jacob 
 
 
 
 
 
 
 
 

  
ABSTRACT 
The common human pathogen, enteroviruses (EVs) are a genus of single stranded RNA 
viruses that include Coxsackie B virus (CVBs). The viral RNA encodes a polyprotein 
containing two viral proteases 2Apro and 3Cpro, that process the polyprotein into structural 
and non-structural proteins during virus replication. Previous research has shown that aside 
from their role in polyprotein processing, the proteases also cleave host proteins in order to 
modulate different cell functions such as translation, transcription and innate immunity. 
 
The innate immune response, and in particular the type 1 interferons (IFN), have an 
important role in controlling virus spread and protecting neighbouring cells from infection. 
Similarly, type III IFNs modulate the permissiveness of cells to CVBs. In paper I, we 
found that CVB3 has evolved a mechanism to evade the type III IFN response in a 
comparable manner to that previously shown for the type I IFNs. This perturbation is likely 
mediated via the proteolytic cleavage of the signal transduction proteins IPS-1 and TRIF by 
2Apro. 
 
When investigating virus-associated diseases, high quality reagents are essential especially 
when the aim is to detect virus in serum or tissue samples. We recognised a need for 
reagents capable of detecting CVBs and in paper II we described the development of CVB 
specific antibodies against 2Apro/3Cpro and show their utility in western blotting, confocal 
microscopy, immunohistochemistry and flow cytometry.  
  
Several observations have suggested a role for CVB infection in the development of type 1 
diabetes (T1D). Interestingly, β-cells infected with CVBs in vitro have defective insulin 
secretion. The aim of paper III was to investigate whether β-cell dysfunction observed 
during CVB infection could be attributed to the activity of the viral proteases. We found 
that the viral proteins 2Apro, 3Cpro and 3A individually exert negative effects on glucose 
stimulated insulin release (GSIS) and voltage stimulated exocytosis in β-cells.  
 
Based on the results in paper I and III, it is evident that 2Apro and 3Cpro have multifaceted 
roles in the viral replication cycle and in the modulation of the host cell. In paper IV we 
wanted to define the viral proteases specific targets in Coxsackeivirus B3 (CVB3) 
permissive cell lines of varied origin (HeLa, CaCo-2 and EndoC-βH1). By enriching for the 
N-terminal peptides using subtiligase labelling combined with LS-MS/MS, we identified 
and validated 81 host cell protease substrates. Among the substrates we identified, the 
protein TCF7L2 was a target of 2Apro mediated cleavage. TCF7L2 is an important 
transcription factor involved in maintaining β-cell functionality and glucose stimulated 
insulin secretion. This finding provides a potential mechanistic explanation for the 
observation that β-cells infected with CVBs in vitro are defective in insulin secretion. 
 
The studies presented in this thesis increase our understanding the molecular virology of 
enteroviruses. Moreover, they open a new chapter of research in examining how disease 
pathology might be caused by the activity of virally encoded proteases. 
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1 INTRODUCTION 
 
The great naturalist and father of taxonomy, Carl Linnaeus once wrote in Philosophia 
Botanica (1751), “natura non facit saltum” which directly translates from Latin into 
“nature does not make jumps”. This statement held onto the belief of the time that species 
were discrete and distinct from each other, as during his creation, God had already set the 
boundaries of the natural world for all that grow and crawl. However, it was through 
Linnaeus own study and systematic cataloguing of nature that he found continuity and 
fluidity of species across the different taxa. Perhaps this seeded the idea that new species 
could develop, since he later on came to cross out the passage “natura non facit saltum” in 
his own copy of Philosophia Botanica. This turned out to be correct a century later when 
Charles Darwin published On the Origin of Species (1859) and the theory of evolution was 
firmly established, stating that all species arise and develop from variation and the selective 
pressure by natural selection. Linnaeus act of crossing out that single passage in his book, 
underpins the most essential aspects of a scientific mind, elastic thinking and scepticism 
against all truths. Now at the start of the 21st century if Linnaeus himself could have access 
to our understanding of modern biology he would be astounded by the complexity but also 
the highly structured architecture of life. Never is this truer then when studying the biology 
of viruses, the most ubiquitous and abundant biological entity on the earth. 
 
From their discovery in the early 19th century, starting with the identification of a few plant 
and animal pathogens, our understanding of viruses has been radically transformed. With 
the advent of DNA/RNA sequencing technology we now know it is very likely that the 
greatest amount of genetic diversity in nature resides within viral genomes (1). 
Furthermore, viruses are polyphyletic (having many evolutionary origins) and infect diverse 
and distant hosts across the tree of life (2). The continued arms race between higher order 
organisms and entities such as viruses over the millennia has been pivotal in shaping a 
diverse and effective immune system (3, 4). As an obligate intracellular parasite, viruses 
interact within the cellular machinery subverting and perturbing some functions whilst 
stimulating others, thereby tightly integrating themselves into the inner working of the cell. 
Therefore, it is through the careful study of the relationships between pathogen and host 
that we can decipher new and exciting biology. Some of the most transformative 
discoveries in immunology and medicine can be directly traced back to these fascinating 
relationships.  
 
The aim of this thesis is to add to our understanding of enterovirus biology especially in 
relation to the virus encoded proteases, defining the role of protease activity in virus 
replication and human disease. Hopefully, part of this thesis work also contributes to the 
new and exciting field of degradomics, the study of proteases and their substrate repertoire 
and ultimately how substrate cleavage shapes cellular function. Four articles form the basis 
of this thesis, paper I describes how CVBs has evolved a mechanism to block the type III 
interferon response upon infection. In paper II the development of two antibodies are 
described that are reactive against the CVB proteases 2Apro and 3Cpro. The utility of these 
antibodies for detecting enterovirus B (EV-B) species in methodologies such as 
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immunohistochemistry (IHC), western blot (WB), flow cytometry and confocal microscopy 
is demonstrated. In paper III the effect of CVB infection and overexpression of viral 
proteases on b-cell function is investigated. The final study, paper IV, is an in-depth 
characterisation of the 2Apro and 3Cpro substrate repertoire in multiple cell lines. 
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1.1 PROTEASES AND THEIR ROLE IN CELLULAR FUNCTIONS  
1.1.1 CLASSIFICATION AND BIOCHEMISTRY 
 
The most fundamental process in regulating the function of a cell is that which is carried 
out by the enzymes that break peptide bonds known as proteases (5).  Proteolysis is the 
most universal of post translational modifications (PTM) of cellular proteins. There are 
exceptionally few proteins resistant to proteolysis and in essence every polypeptide will at 
some point be broken down to its most basic components. Amino acids can then be re-
cycled and re-purposed for translation.  
 
Proteolysis integrates seamlessly into the most crucial processes within a cell such as 
removing signalling peptides and PTM´s from synthesized proteins, allowing for their 
appropriate compartmentalization and function. Proteolytic processing may even target a 
protein into the cell´s secretory pathways or release proteins anchored in the plasma 
membrane, a process known as regulated intramembrane proteolysis (Rip; (6)), which can 
thereby promote cell to cell communication. Many hormones and enzymes are intimately 
regulated by proteolysis as they require the removal of pro-domains to allow them to 
assume their active conformation. It is therefore not surprising that any alteration in the 
expression or activity of a protease may contribute to pathology in many diseases. This 
makes the pursuit of deciphering protease biochemistry and biology a prerequisite for 
understanding general cell physiology as well as tissue pathology in various diseases.  
 
There are over 550 proteolytic enzymes annotated for Homo Sapiens, almost all of which 
are hydrolases, meaning they are biochemical catalysts that use a water molecule to break a 
chemical bond. A typical structure for such an enzyme usually consists of an indentation 
where the active site is located (7). An active site consists of residues either in a triad or 
dyad conformation that participate in a catalytic reaction that breaks a peptide bond. Each 
binding pocket in the protease is numbered S1, S2, S3, S4 (and so on) with S1 being 
located just next to the scissile bond (a covalent chemical bond that can broken). The same 
numbering scheme is used for the substrate binding sites; P1, P2, P3, P4 (8). Interactions of 
substrates with positions outside of the active site important for proteolytic cleavage are 
termed exosites (9).  
 
As it is with most classification schemes there are often multiple ways of categorising any 
biological entity. For proteases one of the most fundamental divisions that can be made is 
by specificity. For instance, if the proteolytic enzyme targets the N- or C- terminus it would 
be defined as an “exopeptidase”, examples of which include (aminopeptidases and 
carboxypeptidases). However, if a peptide bond is hydrolysed inside a peptide chain then 
the protease would instead be labelled as an “endopeptidase” and such proteases include 
pepsin and trypsin. Furthermore, classification can be performed based on the catalytic 
type, meaning the type of residues that occupy the catalytic site; for instance, serine, 
threonine or cysteine types. If occupied by aspartate or glutamate, or if there is a metal ion 
bound to the amino acid side chain, the protease would be named either as aspartyl, 
glutamyl or matrix metalloprotinase (MMP) (10).  
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Compared to other groupings of various enzymes and their families, neither of these 
classifications take note of the evolutionary origin of the different proteases. The most 
generally accepted systematic organisation of peptidases which has been introduced is 
based on sequence homology, and the system that was created based on this organised 
principle is termed MEROPS (11, 12). The system relies on dividing the known peptidases 
into clans and families.   
1.1.2 REGULATION OF PROTEASE ACTIVITY  
 
Since proteases are involved in many processes within a cell and with proteolysis 
essentially being an irreversible reaction it is important that it is tightly regulated. It is 
interesting to note however that there are some enzymes known with ligation activity that is 
either naturally occurring (13) or that that has been engineered (14, 15), although they seem 
to occur much less frequently in nature compared to proteases. Regulation of protease 
activity involves classical mechanisms such as producing proteases as zymogens, which 
require proteolytic processing before they can become active. Proteases can also be 
spatially separated from their substrates through localisation to different cellular 
compartments. Moreover, proteins may act as protease inhibitors by binding to the active 
site of the protease, or the enzyme may be in an inactive state until it is exposed to its 
required co-factor (various ions). For some proteases, additional regions outside the active 
site have been identified where ligand binding can function as an allosteric inhibitor or 
activator. These allosteric binding sites can provide more selective modulation and the 
protease may even be transiently activated (16).  
 
Several classical proteolytic cascades have been described that demonstrate the activation 
of proteases. Most notably, these include the proteases connected to cell death, the cysteine 
proteases (caspases) (17) and pathways involved in blood coagulation which require serine 
protease activity  (18). Another well described proteolytic cascade related to the innate 
immune system is the complement system or the complement cascade, in which, upon 
target recognition, a series of serine proteases are activated (19).  
 
Due to advances in the annotation of substrates that are cleaved by proteases that belong to 
various families, a new view of protease regulation has started to form termed the “protease 
web” (20). Proteases process other proteases, but also cleave inhibitors that act on a diverse 
number of other proteases. This creates complex regulatory circuits with feedback and 
amplification of signals via proteolytic cascades. Therefore, proteolysis within a cell is 
highly interconnected across groups of proteases that even belong to different families, 
making the regulation of any individual protease a highly complex matter. 
1.1.3 CELL DEATH AND PROTEASE ACTIVATION 
 
Initially proteases were thought of as a method for the cell to degrade and recycle proteins 
but as the research field expanded it became clear this was only one role of the proteases in 
biological systems. Now proteases are considered to be equally essential component of 
many cell signalling pathways. This is illustrated very well when considering the process of 
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cell death. It has long been known that caspases have an important role in both the initiation 
and execution of apoptosis (21). As the process of cell death was explored it became clear 
that even proteases outside of the caspase family were involved, such as granzymes (22), 
cathepsins (23) and calpains (24).  
 
Of all the eleven caspases encoded in the human genome, roles for seven of them in the 
process of apoptosis have been described so far (2-3, 7-10) and these caspases can be 
further sub-divided into either initiator caspases (2, 8, 9, 10), or executioner caspases (3, 6 
and 7) (25). The initiator caspases are activated either by the intrinsic (internally triggered 
and mediated via the mitochondrion) or extrinsic pathways (external triggered by ligand 
binding to surface receptor) (26). External signalling by binding of tumour necrosis factor 
(TNF) to the death receptor leads to downstream activation of caspases 8 and 10. In turn 
these proteases mediate the downstream cleavage of effector caspases 3, 6, 7 and caspase 
specific substrate cleavage resulting in apoptosis of the cell. The intrinsic pathway can be 
triggered by different types of cell stress, causing the oligemerisation of BCL2 
Antagonist/Killer 1 (Bak1) and BCL2 Associated X, Apoptosis Regulator (Bax) forming 
pores in the mitochondrial membrane. Released cytochrome c from the mitochondrion in 
turn binds to the apoptotic protease-activating factor 1 (Apaf-1) forming the apoptosome 
thereby activating caspase 3 (27), thereby triggering apoptosis.  
 
Cell death can also be induced in a target cell by the release of cytotoxic granules 
containing serine proteases named granzymes, from cytotoxic T lymphocytes (CTL) (28), 
natural killer (NK) (29) cells or Mucosal associated invariant T (MAIT) cells (30, 31) thru 
the process of CTL-mediated cytotoxicity (32, 33). So far, five different granzymes have 
been identified in humans (A, B, H, K, M) (34, 35) for which only a few the mechanism of 
their cytotoxic activity have been understood. Granzyme A (GZMA), can induce caspase-
independent cell death partly by cleaving mitochondria associated protein (NDUFS3) and 
disrupting mitochondrial metabolism (36, 37). Granzyme B (GZMB) is one of the best 
characterised granzymes and it was first thought to trigger cell death by directly activating 
caspase 3 by cleavage (38). However, follow up studies concluded that it was mainly 
granzyme mediated cleavage of BH3 Interacting Domain Death Agonist (Bid) that 
triggered apoptosis by the intrinsic/mitochondrial pathway (39, 40).   
 
The lysosomal cysteine proteases, cathepsins, are known for their roles in degrading cargo 
in the endocytic pathway and for their involvement in normal protein turnover. Due to 
cellular stress or other triggers such lysothropic agents or viral proteins, cathepsins can 
translocate into the cytosol (41). Interestingly, some cathepsins even retain their proteolytic 
activity at neutral pH (cytosolic conditions) with cathepsins B, L, K and S remaining stable 
outside the acidic lysosomal compartment (42, 43). It has also been demonstrated that the 
proteases B, K, L, and S, along with cathepsin H could possibly cleave Bid (44) providing a 
rationale for how the cathepsins contribute to the induction of apoptosis.  
 
Similarly, the non-lysosomal cysteine proteases that belong to the calpain family can cleave 
the pro-apoptotic protein Bid as well as survival proteins such as Bcl-2 and Bcl-XL (24). 
Direct cleavage of caspase 7 by calpain has been observed, possibly inactivating the 
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caspase (45) providing another example of intersection between calpain activity and 
apoptosis.  
 
These different families and types of proteases are all intricately integrated in orchestrating 
specific outcomes, mainly the initiation and execution of the cell death pathways. It is easy 
to appreciate the depth of regulation for which proteolytic processes directly give rise to by 
alterations seen after extreme or subtle changes in the protease web.  
1.1.4 PROTEASES IN HEALTH AND DISEASE  
 
The type of diseases caused by the deregulation of protease activity are as varied as the 
processes that proteolysis regulates. This observation is most striking when considering the 
hereditary diseases caused by mutations in protease genes (46). Alterations in expression 
patterns or changes in protease structure are the main contributors to the many pathological 
processes including; cardiovascular disease, neurodegenerative disorders, osteoporosis and 
cancer. To provide a comprehensive survey of these pathologies and the mechanistic 
explanations for how proteolysis is involved is well beyond the scope of this thesis. 
However, some representative examples are provided in the following paragraphs, for an 
excellent review on the topic see the following reference (47).  
 
A broad array of proteases ranging from cysteine and serine proteases to metalloproteases 
have been implicated in cardiovascular disease (48). They have been shown to contribute to 
various pathologies through a diverse range of processes such as matrix turnover, cellular 
migration and formation of new blood vessels (angiogenesis).  
 
The causes of the neurodegenerative disorder Alzheimer’s disease (AD) is generally 
unknown. Although that formation of cerebral plaques composed of amyloid β-peptide 
(Aβ) is thought of as a pathological hallmark of the disease (49). Since these plaques are 
inherently derived from the processing of the amyloid precursor protein (APP) there is a 
direct dependency on the proper function of three proteases; α-, β-, and γ-secretases (50, 
51). Therefore, the proteases not only present a direct link to the pathology but also provide 
a target for implementing therapeutic strategies to limit Aβ plaque formation (49). So far, 
such therapeutic strategies have sadly proven ineffective, Verubecestat a β-secretase 
inhibitor did not reduce the cognitive or functional decline in mild-to-moderate patients 
suffering from AD (52). 
 
Osteoporosis is characterized by the loss of bone density and mass due to degeneration by 
osteoclasts as well as inadequate regeneration of the bone matrix by osteoblasts (53). 
Approximately 90% of the bone mass consists of type I collagen fibres, making bone 
vulnerable to the effect of potent collagenases such as the cysteine proteases including 
cathepsins K (54). The proteases expressed by osteoclasts are thought to play a key role in 
the degradation of bone matrix. This has led to the development of compounds targeting 
cathepsin K for use in osteoporosis treatment and such selective inhibitors have entered 
clinical trials (55). As an example, Odanacatib, a caphepsin K inhibitor was recently 
evaluated in a phase III clinical trial in postmenopausal women. The study concluded that 
there were a clinically relevant reduction in bone fractures (56). Although the compound 
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was later discontinued as adverse drug effects had been noted. Regardless the result of the 
study increased the interest for cathepsin K as a potential therapeutic target for osteoporosis 
(57). 
  
Research on the very broad area of cancer has, during the last few decades, demonstrated 
roles for proteases in the early events of tumour growth and the late stages in tumour 
progression, invasion and metastasis (58). The pericellular proteases (such as MMPs) have, 
in particular, been recognized for their importance, since the induced expression of MMP2 
and MMP9 contribute to pericellular proteolysis and remodelling of the tumour 
microenvironment (59).  
 
When studying examples of protease mediated or associated diseases, the realisation comes 
quickly that combined with previously mentioned protease web, cell pathophysiology is 
never isolated but instead interconnected across a multidirectional proteolytic network 
spanning several families of proteases. This underlies the point that only by viewing these 
events as a system of activating and inhibiting reactions it becomes possible to describe the 
outcomes of proteolytic deregulation in any given cell. Moreover, this outcome will also be 
dictated by both the expression as well as the activation state of each individual protease.  
1.1.5 METHODOLOGIES FOR PROTEASE SUBSTRATE DISCOVERY  
 
The early efforts in identifying protein substrates relied predominantly on defining the 
sequence specificities at cleavage sites for individual proteases. In order to extrapolate these 
specificities into novel peptides and experimentally verify a substrate in vitro the 
methodologies applied for this purpose were varied, ranging from expressing peptide 
substrates by phage display (60) to using synthetic peptide libraries (61). There is however 
an inherent limitation with these approaches (aside from being laborious), relating to the 
fact that only one aspect that defines a true cleavage site is tested; namely the primary 
amino acid sequence. The tertiary structure that may either block or facilitate protease-
substrate interactions is not addressed.  It is possible that proteolytic cleavage occurring 
might be entirely dependent on tertiary structure of the protein.  
 
These aforementioned limitations prompted the move into gel-based methodologies, such 
as 2D gel-electrophoresis (62). Separating complex protein mixtures, allows for 
comparative analysis between control and treated samples (those that have undergone 
proteolysis). After proteome separation on a gel, differentially stained spots can be excised 
and analysed by mass spectrometry. Limitations with this approach and variations of it, lie 
in the resolution and sensitivity required to identify substrates, since adequate material is 
needed for the staining and isolation steps. Deriving the cleavage site and thereby the 
protease specificity is also challenging by such methodologies.  
 
Another method for selecting and enriching for proteolytically processed peptides takes 
advantage of the N-termini generated by proteolysis (63). These termini are unique in the 
sense that they are rich in reactive nitrogen atoms at the N-terminal α-amine. It is through 
this property that these free N-termini can undergo reactions and subsequent conjugation 
with various molecules. Several methodologies utilising such conjugation strategies have 
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been developed, with the aim to enrich for peptides that can be subsequently analysed by 
mass spectrometry.  
1.1.6 NEGATIVE SELECTION STRATEGIES  
 
Negative selection of peptides by combined fractional diagonal chromatography 
(COFRADIC) (64) uses the compound 2,4,6-trinitrobenzenesulfonic acid (TNBS) to label 
free N-termini, increasing their hydrophobicity and allowing for their separation by reverse 
phase liquid chromatography (RP-HPLC). Alternative approaches applying negative 
selection have also been developed, an example of this type of methodology being terminal 
isotopic labelling (TAILS) (65, 66). Free N-termini are blocked by dimethylation or  
isobaric tags for relative and absolute quantitation (iTRAQ) labelling, and selection comes 
after the peptides have been blocked and digested with trypsin, in order to be reacted with 
an aldehyde-derivatised polymer. Unbound peptides can then be filtered out and analysed 
by LC-MS/MS and the identification of peptides can thus occur. A caveat of this procedure 
is that the incomplete capture of peptides (thereby incomplete negative selection) could 
potentially cause false positives. 
1.1.7 POSITIVE SELECTION STRATEGIES  
 
Another methodology that has been developed that instead relies on positive selection of N-
terminal target peptides is termed subtiligase labelling (67, 68) (Figure 1). At the heart of 
this method lies a bacterial protease (subtilisin) that has been genetically engineered by the 
introduction of two point mutations (15, 69). These mutations have changed the catalytic 
serine to a cysteine and modified the structure of the catalytic site by exchanging a proline 
in position 225 to alanine. These two modifications abrogate the proteolytic activity of the 
protease and instead provide the enzyme with ligation activity (subtiligase). By utilising 
this enzyme it is possible to specifically incorporate a biotinylated-ester, containing a non-
naturally occurring amino acid (α-aminobutyric acid or Abu) ) at the site of the free amine 
termini generated by the proteolytic cleavage of the protein (70). Positive selection is then 
achieved by capturing the labelled peptides on streptavidin beads with a biotinylated-tag 
designed with a tobacco etch virus (TEV) protease cleavage site. The tag can, via TEV 
protease mediated cleavage, liberate the peptide from the bead. After this cleavage, a 
dipeptide that has the Abu modification, remains attached to the N-terminus which during 
LC-MS/MS analysis can be used for verifying true positives. This negates one of the 
problems with negative selection as the risk for false positives is greatly reduced.  
 
Since the subtiligase labelling is rate limited and the efficacy of the enzyme low, this 
increases the amount of sample protein required for the labelling reaction. This can be a 
bottleneck for extensive and deep coverage of peptides identified if the sample preparation 
is limited. Furthermore, it is known that the subtiligase enzyme has lower activity when 
labelling acidic amino acid (asparagine and glutamine) or branched-chained residues like 
proline, valine and isoleucine (15). Instead the enzyme has enhanced activity against small 
amino acids like glycine, alanine and serine. Recently efforts have been made to counter 
biased labelling specificity of the enzyme by screening point mutants of subtiligase, thereby 
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finding mutants with less biased labelling, these efforts have been successful and improved 
the existing technology (71).  
 
 
 
 
Figure 1. Subtiligase labelling of protein lysates enrich for the free N-terminome of 
proteolytically cleaved proteins. (1) Protein lysates prepared for labelling reaction. (2) 
Intramolecular cleavage of protein by active proteases. (3) Cleavage generates free N-
termini within the protein. (4) Ligation of N-termini with biotinylated peptide ester tag 
(containing TEV cleavage site), reaction catalysed by subtiligase. (5) Binding of tagged 
peptide to agarose streptavidin beads and fragmentation of protein by trypsin/Lys-C 
treatment. (6) Removal of unbound peptides generated by intramolecular cleavage by 
trypsin/ Lys-C. (7) TEV protease cleavage removs peptide ester tag from streptavidin bead 
complex leaving the Abu modification in extreme N-terminus of the captured peptide. (8) 
Analysis by LC-MS/MS.  
 
Undoubtedly the pace at which protease specific substrates and cleavage sites are identified 
for many proteases, has significantly advanced during the last decade. These advancements 
have happened synergistically together with new innovative enrichment methodologies as 
previously described, but also due technical developments in proteomics and mass 
spectrometry. With the generation of large dataset, initiatives like that of the MEROPS 
(12), DegraBase (72)  and TopFind (73) databases, can collect highly annotated 
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degradomes generated under various experimental conditions. Integration of data together 
with rational model building based on our understanding of protease biology hold the 
promise one day describing the complete proteolytic landscape within a cell. It is only by 
studying the whole proteolytic landscape true insight into disease states caused by 
deregulated proteolysis will be gained. Finally, such insights will provide therapeutic 
opportunities for negating the harmful changes occurring within the protease web during 
different pathologies.  
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1.2 THE MOLECULAR VIROLOGY OF ENTEROVIRUSES 
1.2.1 TROPISM 
 
The members of the Picornaviridae family in the genus of enteroviruses are small single 
stranded positive sense RNA viruses. These enteroviruses gain entry into cells via surface 
receptors, and many of these transmembrane proteins have been described poliovirus 
receptor (PVR), Coxsackievirus and adenovirus receptor (CAR), complement decay 
accelerating factor (DAF) and intracellular adhesion molecule 1 (ICAM-1) (74). For a virus, 
the surface receptor is the first requirement in establishing a successful infection. Therefore, 
unsurprisingly, virus entry via receptor binding is an important determining factor in 
dictating host and tissue tropism. In the case of poliovirus, PVR that is expressed by 
lymphoid tissue of the gastrointestinal tract enables the virus to gain access to the cells 
thereby establishing the primary site of infection (75, 76). If later, the poliovirus infection 
becomes systemic then the neuronal cells (expressing PVR) can also be infected. However, 
it is too simplistic to regard the permissiveness of a cell to virus infection as solely due to 
the expression of a surface receptor, as other intracellular host proteins are needed for the 
successful completion for viral replication (77, 78). Factors that regulate the ability of a cell 
to sustain viral propagation may be modulated further by external immunoregulatory 
molecules like the interferons (79). Surveying the literature, it is clear that enteroviruses in 
both in vitro cell culture as well as in vivo animal models, can infect and replicate in a 
broad range of cell types and hosts (80). 
 
1.2.2 REPLICATION AND PROTEOLYTIC PROCESSING OF THE VIRAL 
POLYPROTEIN 
 
Upon entry into a cell, the virus capsid undergoes uncoating which may be conditional on 
acidification of the endocytic compartment, depending on enterovirus species (81, 82). 
Conformational changes in the capsid facilitate the interaction of the structural proteins 
VP1 and VP4 with the endocytic membrane (83–85). This allows for the release of the 
positive sense viral RNA (approximately 7.4 kb in size) into the cytosol. The viral RNA is 
then used directly to produce the viral polyprotein by cap-independent translation mediated 
by RNA secondary structures termed internal ribosome entry site (IRES) (86). For the last 
50 years it was thought that enteroviruses encoded one open reading frame (ORF) that 
makes the polyprotein, but recently this long-established dogma was disproven after the 
identification of an additional ORF encoding a 56-76 amino acid long (predicted) 
transmembrane protein, present in some enterovirus species (87). This factor, designated as 
upstream open reading frame (uORF) protein, is thought to be important in facilitating 
efficient virus release from an infected cell. 
 
The enterovirus polyprotein is divided into different regions (Figure 2) that consist of the 
structural capsid proteins in the P1 region (VP4-VP1), and the non-structural proteins in the 
P2 region (2A-2C), together with the P3 region (3A-3D) (88). Processing of the viral 
polyprotein by the viral encoded proteases 2Apro and 3Cpro generates the individual 
functional proteins. An interesting exception from this mode of polyprotein processing can 
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be seen with foot-and-mouth disease virus (FMDV) (89, 90). In the polyprotein of FMDV, 
P1 and P2 separation is not mediated by 2Apro proteolytic cleavage, but instead it is caused 
by a series of amino acid residues located within the 2Apro sequence that prevent the linking 
of the P1 and P2 segments during translation. This process is termed “ribosomal skipping” 
and has been observed in multiple positive and negative RNA stranded viruses (91).  
 
Collectively, the structural and non-structural viral proteins translate the viral RNA, 
modulate the host cell to facilitate the replication (92), subvert the cell innate immune 
response (93), and finally initiate encapsidation and formation of new infectious virions 
(94). Release of newly formed virions was traditionally thought to mainly occur by cell 
lysis, however this classical view is being challenged, as observations have been made 
suggesting that viruses can be shed in extracellular vesicles (EVs) (95, 96), offering an 
alternative method of viral dissemination. Further support of the latter mode of transmission 
comes from reports that enteroviruses can establish persistent infections in both tissue and 
cell models with little cytopathic effects (97–99).   
 
 
 
Figure 2. Schematic depicting the organisation of enterovirus RNA and polyprotein, 
highlighting sites of proteolytic processing attributed to 2Apro and 3Cpro. RNA secondary 
structures (IRES) indicated outside the polyprotein segments, with the non-structural 
protein, viral protein genome linked (VPg) coloured red. Cuts in the polyprotein is 
highlighted by the colours purple (2Apro) yellow (3Cpro) with black colour indicating 
autocatalytic cleavage.  
1.2.3 THE VIRAL ENCODED PROTEASES 2APRO AND 3CPRO 
 
For most enteroviruses, the processing of the polyprotein is divided between the two viral 
encoded proteases 2Apro and 3Cpro. The scissile bond between VP1 and 2A is cleaved by 
2Apro, whereas all other sites separating the different viral proteins are cleaved by 3Cpro 
(Figure 2) (93). Processing of VP0 into VP4 and VP2 is an exception as neither of the two 
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proteases have been shown to cleave VP0, instead structural modelling has inferred that this 
event occurs autocatalytically (100). The discovery and mechanism of this process is 
discussed in detail in chapter 1.2.4.  
 
Structurally and biochemically, the enterovirus proteases 2Apro and 3Cpro both belong to the 
chymotrypsin-related endopeptidases. Each protease is comprised of two separate domains 
(Figure 3). The structural elements themselves are made up of antiparallel β-sheet barrels, 
together with a β-sheet pile for 2Apro and a conserved ion binding domain in both proteases 
(zinc ion for 2Apro and chloride ion for 3Cpro). The structure of both 2Apro (101)  and 3Cpro 
(102) proteases have been solved multiple times for different species of enteroviruses and 
can be found in the protein data bank (PDB) (103). Conservation of 2Apro and 3Cpro 
sequences between different species of the same genus ranges between 50-75% (93). 
Moreover, the region in the vicinity of the catalytic site is partially conserved for both 2Apro 
and 3Cpro within the enterovirus genus. This suggests that sequence specificity, and in 
addition substrate specificity and repertoire, may be similar irrespective of the enterovirus 
species. Indeed, this has been documented within the scientific literature as multiple 
substrates are shared between enteroviruses. Examples of such conserved substrates are 
discussed in chapter 1.3.2 (93).  
 
 
 
Figure 3. Sequence alignment and graphical representations of 2Apro and 3Cpro structure. 
(a) and (b) Primary sequence alignment of a representative sequence from each virus 
species in the enterovirus genus. The structural features of the catalytic triad and ion 
binding amino acids are highlighted with arrows. (c) and (d) topological schematic over 
2Apro and 3Cpro. (e) Ribbon model of Enterovirus 71 (EV71) 2Apro (PDBID: 4FVB). (f) 
Ribbon model of CVB3 3Cpro (PDBID:2VB0). (g) and (h) Surface representations of each 
protease with the active site of marked in yellow. Figure adapted from (93) with 
permission.  
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Efforts have been made to develop tools able to predict novel substrates based on the 
sequence cleavage specificity of the 2Apro and 3Cpro proteases, the most notably tool being 
the NetPicoRNA server (104). Relying on the available polyprotein sequences of annotated 
enteroviruses, the authors applied a neuronal network algorithm to define amino acid logos 
as well as the surface accessibility of the cleavage site within the polyprotein. This work 
highlighted the importance of the conserved amino acid identities at positions P4, P2, P1, P1´, 
P2´, especially for 2Apro where the P1 amino acid was exclusively a glycine whereas the 
3Cpro logo was characterised by a glutamate in position P1 and glycine at P1´. A tool like the 
NetPicoRNA server has allowed researchers to investigate the susceptibility of cellular 
proteins of interests to cleavage by the enterovirus proteases 2Apro and 3Cpro. Since the tool 
was published in 1996, the server has now been discontinued. But with the advancements in 
computational analysis in the area of machine learning and with the availability of more 
extensive datasets of protease substrates, it is very likely that more accurate and refined 
prediction algorithms will be implemented in the near future. In fact, such tools are already 
available (iPROT-Sub, PROSPERous, PeptideCutter) for a range of endogenous protease 
substrates (105–107). 
 
Determination of the protease specificity based on cut sites in the polyprotein provides 
logos for the amino acids which are accepted (or preferred) in the cut site. Ultimately 
however this approach could be somewhat misleading in predicting new cellular substrates, 
since the conservation of amino acids in the cut sites can be due to evolutionary constraints 
rather than the connection with protease cleavage. The type of logos that rely exclusively 
on viral polyprotein sequences may therefore be limited, and this holds further truth as the 
higher order structure (HOS) of the substrate is not incorporated into this type of 
predication model. Hopefully, as more protease substrates are structurally determined it will 
become possible to identify patterns in tertiary structures and as such improve the existing 
in silico prediction tools. 
1.2.4 THE AUTOCATALYTIC CLEAVAGE OF VP0 
 
The definition of autocatalysis is a reaction in which the product is the catalyst for the same 
reaction. In a classical study (108) published in 1968 the mechanism by which poliovirus is 
processed started to be elucidated. It was evident from pulse chase experiments performed 
within a short time frame (30min) viral polyprotein is processed by some mechanism. In the 
same study the capsid protein VP0 was identified, but it took two more years before the 
same authors could show that VP0 gave rise to the smaller capsid proteins VP2 and VP4 
(109). For many years not much work was done to investigate the process from which VP2 
and VP4 is generated from VP0. It was clear however from cell-free experiments in extracts 
from rabbit reticulocytes that processing did not take place solely by the expression of full-
length polyprotein (110).  
 
Eventually the hypothesis was proposed that cleavage of VP0 would only occur during the 
final assembly of virions containing RNA (111). Late in the year of 1981 another study 
could by partial amino-terminal sequencing determine the amino terminus of each capsid 
protein (112). It was concluded that cleavage of VP0 was distinct from other cleavages in 
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the polyprotein, again pointing to its direct connection with viral morphogenesis. The same 
authors succeeded in producing infectious poliovirus particles by cell-free translation of 
poliovirus RNA in HeLa cell extract. In these experiments accumulation of VP0 and faint 
amounts of VP2 could be detected by SDS-PAGE (112). This was an advance in the field, 
since other research groups had only succeeded in assembling immature capsid 
intermediates (containing uncleaved VP0) (113, 114).  
 
As the provirus structure VP0 is uncleaved, these capsids were not as stable as mature 
virions at elevated temperature, detergents and high pH (113). These biochemical properties 
made them difficult to isolate and study. This issue was circumvented in 1994 with the 
development of a specialized protocol (100), allowing the isolation and crystallization of 
the empty capsid intermediates at a 2.9 Å resolution. A structure was modelled in which 
VP0 was intact and based on this structure the hypothesis that the cleavage was 
autocatalytic in nature proposed.  
 
The hypothesis was based on four key observations. First, close to the VP0 scissile bond 
there is a histidine side chain that could potentially catalyse the hydrolysis of the bond. 
Second, solvents were detected between the bond and the histidine (potentially water). 
Third, there are two carbonyl oxygen atoms oriented in the same direction that upon ligand 
binding could increase the positive charge in the scissile bond and accelerate hydrolysis. 
Fourth, within the depression beneath where the scissile bond resides there are hydrophobic 
residues, strengthening the possibility that ligands could bind to the site, such as RNA. This 
would be in line with the previous postulations that cleavage is RNA dependent. Based on 
the observations made from this structural modelling the hypothesis that VP0 cleavage is 
autocatalytic in nature was firmly established.  
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1.3 ENTEROVIRUSES AND THE HOST CELL 
1.3.1 VIRAL ASSOCIATION WITH TYPE 1 DIABETES DEVELOPMENT 
 
Of all the infectious diseases known to affect humans, some of the most common can be 
attributed to viruses belonging to the Picornaviridae family, especially those within the 
enterovirus genus. The common cold, poliomyelitis, myocarditis, meningitis, and hand–foot 
and mouth disease (HFMD) are to name but a few diseases caused by enteroviruses (115). 
In addition chronic and inflammatory diseases related to autoimmunity, type 1 diabetes 
(T1D), allergies and exacerbations in asthma have also been associated with enterovirus 
infections  (116). 
 
T1D is a chronic disease caused by the loss of insulin secreting β-cells in the pancreas 
resulting in an inability to correctly regulate blood glucose levels. The association between 
enteroviruses and especially Coxsackievirus B (CVB) and T1D is longstanding as the first 
report dates back to the late 1960s. In the study it was shown that, the incidence of CVB4 
specific antibodies significantly correlated with the seasonal disease presence and onset of 
juvenile diabetes (117). In this study, one should note that of the six serotypes within the 
CVB group, five were tested and the serology of CVB1, CVB2, CVB3 and CVB5 did not 
show significant correlations. Further epidemiological and clinical studies trying to 
substantiate this association have been conducted with varied outcomes (118).  
 
In 2004 a systematic review was conducted on the CVB serology in connection to T1D 
development examining 26 case-control studies published between the years 1966-2002 
(119). The authors concluded that the evidence was too inconsistent to convincingly prove 
an association. About 7 years later another meta-analysis surveying observational molecular 
studies (24 studies and 2 abstracts from 1965 to 2010) measured two outcomes, enterovirus 
association with either T1D or autoimmunity (120). Despite variation in study design and 
statistical heterogeneity across/between the studies, significant associations between 
enterovirus infection and T1D, as well as autoimmunity, could be substantiated. 
 
In a more recent example, the Diabetes Virus Detection (DiViD) study (121) in which a 
small pancreatic biopsy was collected from adults with recent onset diabetes, enterovirus 
RNA was detected by RT-PCR in four out of the six donors (122). Viral capsid protein 
(VP1) positivity in pancreatic islets was also detected in all six donors by 
immunohistochemical (IHC) staining. However concerns have been raised about the 
reliability of these findings as positivity for viral RNA (by RT-PCR) was only found in one 
out of six donors in the biopsy sample (123). The former report documenting RNA 
positivity in four out of the six cases came from the analysis of media in which the isolated 
islets had been cultured in prior to use in functional assays (105), whereas the results in the 
latter report were obtained directly from the biopsies (106). Due to the inconsistency in the 
results despite same detection method for viral RNA, laboratory contamination cannot be 
ruled out. 
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Many of the observational molecular studies conducted so far have relied upon the use of a 
particular VP1 antibody (clone 5D8/1, Dako). It has been reported that this specific 
antibody cross-reacts with endogenous mitochondrial antigens (124). Non-specific staining 
for the 5-D8/1 clone have also been reported to occur in IHC when using heart tissue 
derived from both mouse and human (125). This raised concerns about the validity of 
studies utilising this reagent, although it has been argued that under optimised experimental 
conditions it is likely that detection is reflective of presence of enterovirus antigens in 
infected tissue (126). VP1 positive islets have been found in tissue derived from patients 
with both type 1 and type 2 diabetes, although with a higher frequency in T1D (127). This 
antibody was also used in the DiViD study, and interestingly all six donors and two out of 
the nine non-diabetic controls were positive for VP1 in islets (122). This make cross-
reactivity of the VP1 antibody difficult to exclude and as such results from studies 
employing this reagent should be interpreted with caution.  
 
It is challenging to summarise over 50 years of research examining the link between type 
T1D development and enterovirus infections as the results have been as varied as the 
studies conducted. To date such a causal link has yet to be convincingly proven although a 
substantial amount of circumstantial observations have been reported. If such an association 
holds true however, several mechanisms through which enteroviruses could trigger T1D 
have been proposed (128). One process could be via the direct cytolytic infection of β-cells 
causing cell lysis and thereby disease development. Perhaps a more likely scenario that ties 
in with the conventional understanding of T1D pathology as an autoimmune condition 
(129, 130) would be an autoimmune response triggered by an enterovirus infection. 
Prolonged persistent infections of enteroviruses in various tissues have been observed, in 
for instance the heart, gut and pancreas (131–133). If β-cells would sustain a persistent 
infection it could potentially break self-tolerance by presenting viral antigens via major 
histocompatibility complex (MHC) class I, thereby exposing the cell to the immune system. 
There is also the possibility that a viral antigen shares an immunogenic epitope with a host 
protein. This could lead to bystander activation causing activation of autoreactive T and B 
cells and subsequent β-cell destruction (134).  
1.3.2 ENTEROVIRUS IMMUNE EVASION STRATEGIES 
 
The first main obstacle that an invading pathogen faces upon entering the host cell is innate 
immunity and the need to overcome the interferon (IFN)-mediated antiviral response. This 
response consists of the recognition of viral nucleic acids, known as pathogen-associated 
molecular patterns (PAMP). These PAMPs, in the case of picornaviruses, are detected by 
intracellular proteins known as pattern recognition receptors (PRRs) that consist of the toll 
like receptors (TLRs), a large family of receptors (e.g. TLR3, TLR7, TLR8 and TLR9) to 
name a few, all of which have their own preference for specific PAMPs. Cytosolic retinoic-
acid inducible gene I (RIG-I) or melanoma differentiation-associated 5 (MDA5) are other 
known PRRs (135). The recognition of viral nucleic acids by PRRs then leads to the 
production and secretion of Type I interferons (IFNs), and thus by either autocrine or 
paracrine signalling through the type I IFN receptor (IFNAR), an antiviral state is induced 
in the target cells, promoting restriction of viral replication or virus clearance (136, 137).  
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The ways in which enteroviruses counter the host antiviral response are diverse (Figure 4). 
However, a strong theme in the different strategies that enteroviruses have evolved to 
perturb innate immunity responses revolves around the employment of the virus encoded 
proteases 2Apro and 3Cpro. During infection with different enteroviruses, such as poliovirus, 
CVB3 or EV71, the viral sensors RIG-I and MDA5 are directly cleaved by 3Cpro (138, 139) 
and MDA5 by 2Apro respectively. Other proteins involved in inducing and mediating the 
IFN response are likewise targeted. For instance, RIG-I/MDA5 downstream signalling  
proteins  such  as  mitochondrial antiviral signalling protein (MAVS) is cleaved by 2Apro 
(139–141). Moreover, the recognition of viral nucleic acid in the endocytic compartment by 
TLR3, is blocked by 3CPro cleavage of the signalling adaptor protein, TIR Domain 
Containing Adaptor Inducing Interferon-Beta (TRIF). Even at the level of transcription 
factors, several proteins involved in the activation of interferon transcription are targeted by 
the proteases, like IRF7 (142, 143) and IRF9 (144) which are both susceptible to cleavage 
by 3Cpro in EV71 infections. These observations demonstrate the multiple intersections 
between the viral proteases and innate immune signalling pathways, with protease mediated 
modulation seen in the early stages of recognition, during the propagation of signals and 
finally when activation of interferon transcription occurs.  
 
Aside from interfering with innate signaling pathways, enteroviruses can also modify host 
gene expression to perturb interferon production at the stage of RNA processing and 
trafficking. Enterovirus encoded proteases are involved in disrupting RNA polymerase I, II, 
and III transcription (145–147). Several host proteins involved in transcription have been 
identified as viral protease substrates shedding light on how the disruption of transcription 
is accomplished (92). Moreover, during enterovirus infection nucleocytoplasmic transport 
is altered with the subsequent accumulation of some certain host factors in the cytoplasm. 
These host factors either stimulate the IRES-mediated translation of viral polyprotein or 
mediate the switch between viral translation and RNA replication, and include La 
autoantigen  (La) (148–151), Poly(RC) Binding protein 2 (PCBP2) (152–154), and 
polypyrimidine tract binding protein 1 (PTB) (155, 156), Splicing Factor, Arginine/Serine-
Rich  20-kD (SRP20) (157). The precise process by which nucleocytoplasmic transport is 
modified during infection is complex and not fully understood, but it is thought that in part, 
it is due to the proteolytic cleavage by 2Apro of several proteins, such as Nup62, Nup98 and 
Nup153, which are part of the nuclear pore complex (NPC) and this has been described for 
both poliovirus and rhinovirus (158–160). 
 
A central theme in the enterovirus replication cycle is the shutting down of host translation, 
thereby effectively blocking the expression of antiviral genes. This modulation needs to be 
balanced and precise as the same cellular machinery is also adopted by the virus to produce 
it’s viral mRNA and proteins. In exerting control of host translation, enteroviruses have 
evolved to cleave the translational initiation factors such as, eukaryotic translation initiation 
factor 4 G (EIF4G) and poly (A)-binding protein (PABP) (161). EIF4G is a central 
scaffolding protein essential for the recruitment of the cap-binding protein eIF4F to the 
ribosome and the mediation of cap-dependent translation (162), hence, cleavage of EIF4G 
represses cap-dependent translation. To achieve complete blockage of cap-dependent 
translation, PABP likewise cleaved by the viral proteases. PABP binds the 3 ́ poly (A) tails 
of host RNA transcripts, forming the loop structure of actively translating mRNAs. PABP 
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cleavage has been attributed to both 2Apro and 3Cpro in poliovirus and CVB3 infection (142, 
163). Viral protease mediated cleavage events are on the other hand not the only mode 
through which enteroviruses can modulate host translation. Enterovirus induced expression 
of host micro RNA miR-141 which leads to down-regulation of the translation initiation 
factor eIF4E which in turn negatively impacts cap-dependent translation while leaving cap-
independent translation unaffected (164). 
 
 
 
 
Figure 4. Viral replication cycle and innate immune evasion. (1) Entry of the virus into 
the cell mediated via transmembral surface receptors leading to the release of viral RNA 
into cytoplasm. (2) Cap-independent translation and subsequent processing of viral 
polyprotein into functional structural and non-structural proteins. (3) Modulation of innate 
signalling pathways, leading to the perturbation of the interferon response. (4) Replication 
of viral RNA and packaging into newly formed virions. (5) Release of virus progeny either 
by cell lysis or by extracellular vesicles. Figure adapted from (93) with permission. 
 
Several strategies used by enteroviruses, to achieve immune evasion have been discussed 
here, namely the interruption of innate signalling pathways, and the direct targeting 
transcription or translation. The examples given were chosen on the basis of the 
involvement of the viral proteases in each evasion strategy. There are however more 
unconventional ways in which enteroviruses have evolved to evade detection or counter an 
immune response. It has been shown that enteroviruses such as CVB3 and EV71 can be 
contained in and therefore disseminated from an infected cell through the shedding in 
extracellular vesicles (165, 166) thereby possibly avoiding their detection by neutralising 
antibodies. Interestingly EV71 produces vesicles enriched in miRNA-146A, a micro RNA 
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with the ability to suppress the expression of interferon I, thereby  promoting  viral  
replication and spread (165). These are just some of the ways in which enteroviruses have 
evolved to circumvent an effective immune response during infection. Although there have 
been many advances in our understanding of these processes over the decades, much 
remains to be discovered, especially in regards of finding new viral protease substrates 
which upon targeting could perturb the innate immune response. 
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2 AIMS OF THE THESIS 
 
The body of work that makes up this thesis has as its objective to provide insights into 
enterovirus biology and to elucidate the relationship between infections and human disease. 
The experimental work focuses on defining the viral protease substrate repertoire and 
provides mechanistic explanation of how enteroviruses may cause b-cell dysfunction, in the 
possible context of T1D development.  
 
Specific aims: 
 
Paper I: To investigate if CVBs are capable of perturbing type III interferon production 
upon infection by subverting innate immune signalling pathways via the activity of virus 
encoded proteases 2Apro and 3Cpro. 
 
 
Paper II: To develop highly specific antibodies against the viral encoded proteases 2Apro 
and 3Cpro, that could be used in a wide variety of methodologies for enterovirus detection. 
 
 
Paper III: To investigate the impact that CVB infection and the ectopic expression of viral 
proteases 2Apro and 3Cpro have on b-cells and their capacity to secrete insulin. 
 
 
Paper IV: To perform a thorough survey of the CVB specific 2Apro and 3Cpro substrate 
repertoire in multiple cell lines. Furthermore, to explore the functional impact that changes 
in the proteolytic landscape might have on the infected cell and how this might relate to 
human disease. 
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3 METHODOLOGICAL APPROACH  
3.1 ETHICAL CONSIDERATIONS 
 
In paper II experiments were conducted using materials derived from the following murine 
model strains, C57BL6 (JAX stock #000664) and non-obese diabetic mice (NOD) (167). 
These mice were kept according to institutional and national regulatory guidelines and with 
appropriate ethical permission. In paper III, infection experiments were carried out using 
human pancreatic islets isolated from organ donors by the Nordic Network for Clinical Islet 
Transplantation, Uppsala University. All experiments using human derived material were 
conducted according to the ethical directives described in the Declaration of Helsinki and 
approved by the regional ethics committee. The numbers for the relevant ethical 
applications submitted are as follows: Dnr. S46-14 (paper II), Dnr. 489/03 (paper III). 
3.2 VIRUSES 
 
The well characterised and widely used CVB3 strain Nancy was used in nearly all studies 
(paper I, II III) with the addition of CVB4 E2 in paper III. In paper IV in the infection 
experiments the virus strain used was CVB3 Woodruff encoding a non-fused enhanced 
green fluorescent protein (EGFP) as a marker (168). In paper IV Vesicular Stomatitis 
Virus (VSV-GFP) was also used (169). In paper II a cell array containing GMK, HeLa and 
RD cells infected with various virus species was utilised (170). For all of the virus stocks 
used in the different studies, the viruses had been propagated and titered in HeLa cells. 
3.3 CELL LINES 
 
Depending on the experimental context and hypothesis tested, various cell lines were used. 
In paper I and paper II, HeLa cells were used as a cell model as they are highly 
permissive to CVBs and can mount an intact type III interferon response upon viral 
infection (171). For the studies examining insulin secretion after CVB infection (paper III) 
the rat b-cell line INS-1 832/13 was chosen as a model due to its previously established 
suitability in examining b-cell insulin secretion (172). In the final study (paper IV) that 
aimed to define the protease substrate repertoire three different cell lines were included: 
HeLa, CaCo-2 (human epithelial colorectal adenocarcinoma cells) and EndoC-βH1 
(genetically engineered human beta cell line) (173). 
3.4 IMMUNOCYTO- AND IMMUNOHISTOCHEMISTRY 
 
In probing CVB infected pancreatic tissue in paper II immunocyto- and 
immunohistochemistry were used. Tissue that had been formalin fixed and paraffin 
embedded (FFPE), sectioned, heat-fixed and treated for antigen retrieval. The antibodies 
developed against the proteases had been titered for optimal performance and detected by a 
biotinylated anti-rat IgG antibody. Visualization could then be achieved by using a 
horseradish peroxidase-coupled streptavidin reagent.  
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3.5 RNA ISOLATION AND REAL-TIME PCR 
 
Expression of interferon induction, cellular surface receptors in paper I or the presence of 
viral RNA, insulin in paper III were estimated by isolating RNA from samples and using 
RT-PCR as described in  (141, 174). 
3.6 FLOW CYTOMETRY 
 
To validate robust infection of target cells with CVB in paper I, II, IV, cells were fixed in 
paraformaldehyde and analysed by flow cytometry. VP1 or EGFP tagged virus were 
detected using BD FACS Calibur or BD Accuri, analysis of data was performed with the 
FlowJo software, version 10. 
3.7 WESTERN BLOT 
 
To detect proteins as well as cleavage products, western blot was performed in paper I, II, 
III, IV according to standard procedure (175) separating protein lysates by SDS-PAGE and 
transferring proteins to polyvinylidene difluoride (PVDF) membrane using the I-BLOT 
system (176). Paper IV utilised protein transfer to nitrocellulose membrane and for protein 
detection and for quantifiable fluorescence based western blot (QFWB) the modern LI-
COR Odyssey (177) was used. 
3.8 MONITORING OF HORMONE SECRETION 
 
The degree of insulin release was evaluated by stimulating b-cells with glucose and then 
measure insulin content in media by enzyme-linked immunosorbent assay (ELISA). In 
paper III glucose stimulated insulin secretion was carried out using islets from organ 
donors or INS-1 832/13. Due to the technical difficulties in performing this study multiple 
complementary methodological approaches were applied as described below.  
 
First, to evaluate the effect of viral proteases on insulin secretion, INS-1 832/13 cells were 
transfected with constructs containing 2Apro or 3Cpro. These experiments were problematic 
due to low transfection efficiency (10-15%). In order to address this issue cells were co-
transfected with a construct containing human growth hormone (hGH). This approach has 
previously been used as a proxy for evaluating secretion as hGH, when ectopically 
expressed, is co-secreted with insulin (178). This made it possible to study insulin secretion 
despite low transfection efficiency. 
 
Secondly, to further evaluate the effect of viral protease expression on the secretion of 
individual INS-1 832/13 b-cells, patch clamp studies were conducted. Patch clamp is an 
electrophysiological method used to monitor ion currents by measuring changes in the 
overall capacitance of a living cell and subsequently depolarization and insulin secretion 
(179). b-cells were first transfected with non-structural viral proteins. The day after 
transfection individual cells that were GFP positive were pierced with a fine glass pipette. 
As transfection of b-cells with 2Apro were both cytotoxic and blocked efficient protein 
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translation, the patch clamp studies were carried out by adding active recombinant 2Apro to 
the pipette.  Calcium currents were evaluated by depolarising cells from -70 mV or -50 mV 
to +50 mV for 50 ms. To study exocytosis the cells were subjected to a sequence of 
depolarisations ranging from -70 mV to 0 mV. As insulin granules dock with the plasma 
membrane and release their cargo to the extracellular space, the cell surface area changes 
and thereby the cell membrane capacitance, which indirectly indicates the secretion 
efficiency. 
 
Thirdly, validation of previous results generated from patch clamp experiments was 
performed by an independent method applying total internal reflection fluorescence (TIRF) 
microscopy (180). This allows for the monitoring and quantification of cell surface events 
such as fusion of insulin granules with the plasma membrane.  
3.9 SUBTILIGASE LABELLING  
 
In paper IV for the purpose of protease substrate discovery, we applied a method known as 
subtiligase labelling (67). As newly translated proteins become acetylated at the a-amino-
termini, any unblocked peptides will be mainly produced after proteolytic cleavage. This is 
a feature exploited in this labelling strategy. Through the activity of the genetically 
engineered subtiligase enzyme, unblocked N-termini are labelled with biotinylated 
synthetic peptide (harbouring an amino acid sequence ENLYFQS) and a non-natural amino 
acid mass tag (α-aminobutyric acid, Abu). Peptides are then bound on streptavidin beads 
and later released by TEV protease mediate cleavage within the TEV recognition site 
(ENLYFQ↓S). This approach is designed to enrich the N-terminal side of peptides in 
complex samples by a catch-and-release strategy for further peptide identification by LC-
MS/MS. A comparison with other substrate discovery methodologies and a more detailed 
description and discussion regarding of subtiligase labelling can be found in section 1.1.7 of 
this thesis.  
3.10 LENTIVIRUS TRANSDUCTION 
 
In order to stably express a protein that was resistant to 2Apro and 3Cpro cleavage (and 
thereby prevent protease mediated cleavage) in HeLa cells, lentivirus transduction was used 
in paper IV (181, 182). 
3.11 BIOINFORMATIC ANALYSIS 
 
For figure generation and statistical testing in papers I and III, the commercially available 
GraphPad software version 8 was used. In paper IV custom code was written using the 
scripting language python (3.6), aside from the python standard library several other 
libraries were implemented. These include (but are not limited to), Pandas (183), Matplotlib 
(184), Numpy (185) and Networkx (186). In the R (3.5) scripting language the following 
packages were utilised for gene ontology enrichment analysis and pathway analysis; 
Disease Ontology Semantic and Enrichment analysis (DOSE; (187) and ReactomePA 
(188). Publically available databases such as DisGenet (189), DegraBase (72), IntAct (190), 
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and Reactome (191) were also integrated into the analysis pipeline. For generating amino 
acid sequence logos the R package ggseqlogo was implemented (192). Statistical analysis 
was performed using the python library SciPy (193) or by built in statistical test in the 
software Prism. 
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4 RESULTS AND DISCUSSION 
 
In the four papers in my thesis, I have investigated different aspects of enterovirus biology. 
With a special focus on studying the proteolysis mediated by viral proteases and which role 
substrate cleavage events have in the virus replication cycle. In paper I it is shown how 
CVB3 has evolved mechanisms to block type III interferon expression during infection and 
how 2Apro are directly involved in perturbing the innate immune response. Paper II reports 
the development of 2Apro and 3Cpro specific antibodies and their utility in detecting EV-B 
species in a range of methodologies. Paper III is an investigation of the cellular 
dysfunction observed in insulin secreting b-cells during CVB infection, showing that the 
viral proteases may contribute to this phenotype. Finally, paper IV is a comprehensive 
survey of the 2Apro and 3Cpro specific substrate repertoire in multiple cells lines. 
Collectively, these papers define the host protein cleavage events mediated by the viral 
proteases and their functional/phenotypic relevance is explored in the context of enterovirus 
associated disease. 
4.1 COXSACKIEVIRUS COUNTERS THE HOST IMMUNE 
RESPONSE BY BLOCKING TYPE III INTERFERON 
EXPRESSION (PAPER I)  
 
The arms race between viruses and their hosts has led to co-evolution and an intricate 
balance in the interactions between pathogen and host, with each attempting to counter the 
actions of the other. For enteroviruses, as previously discussed in the introduction (chapter 
1.3.2), immune evasion is multifaceted and occurs at multiple points during the virus 
replication cycle. In an excellent study from 2011 by Mukherjee et al. (140), it was 
demonstrated that CVB3 attenuates the host response by cleaving MAVS (also known as 
IPS-1) and TRIF via 3Cpro activity during infection, thereby perturbing innate immune 
signalling. Ultimately this perturbation of key adaptor molecules blocked the type I 
interferon response rendering the cells susceptible to infection.  
 
The type III interferon (IFN-λ) family have been shown to exert broad antiviral activity, 
especially at mucosal surfaces where the IFN-λs are predominantly expressed (194, 195). 
The primary infection site for enteroviruses is the gastrointestinal tract and we therefore set 
out to investigate if, in a similar manner to the type I IFNs, CVB3 was capable of blocking 
type III response.  
 
HeLa cells were chosen as a model system since the cell line is readily infected by 
enteroviruses. Detection of CVBs in mammalian cells is accomplished by PRRs such as 
MDA5, RIG-I and TLR3, that sense single or double stranded viral RNA. To simulate the 
uncoating of endocytosed virions, Polyinosinic:polycytidylic acid (poly I:C), a RNA double 
stranded mimic, was used to stimulate the cells. Poly I:C was added directly to the culture 
media, to be taken up into the cells by endocytosis and thereby allowing detection by TLR3 
localised to the endocytic compartment. To facilitate detection by the cytosolic RIG-I and 
MDA5 the RNA double stranded mimic was also transfected into the cells. Poly I:C 
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treatment but not CVB3 infection was able to induce the expression of type III IFNs (Figure 
1). Indeed, if cells were infected prior to treatment with poly I:C there was a significant 
reduction in the IFNλ1, IFNλ2 and IFNβ mRNA expression (Figure 2), indicating that 
CVB3 actively inhibited the induction of type I and type III IFNs.  
 
Earlier studies reported that the expression of type III interferons is dependent on IRF3 
activation due to hyperphosporylation of the protein at multiple sites (196). By western blot 
analysis it was observed that CVB3 infection blocks this hyperphosphorylation event 
(Figure 3B). Due to the alterations in the phosphorylation state or IRF3, further upstream 
signalling proteins were evaluated by western blot. These experiments showed clear 
reduction in the protein levels of TRIF and IPS-1 (Figure 4A, B), and interestingly smaller 
sized protein fragments were also detected. These fragments were thought to be cleavage 
products of the full length TRIF and IPS-1 proteins. Moreover, the appearance of the 
cleavage fragments was independent of caspase and proteasome activity during CVB3 
infection, as treatment of cells with chemical inhibitors of apoptosis and proteasome 
degradation did not rescue the expression of TRIF or IPS-1 (Figure 5).  
 
Overexpression of 2Apro or 3Cpro by cloned constructs transfected into HeLa cells showed 
that 2Apro robustly dampened the mRNA expression of IFNλ1, IFNλ2 and IFNβ following 
poly I:C treatment whereas no effect was observed when overexpressing 3Cpro (Figure 6A 
,B ,C). To further support the hypothesis that 2Apro was the protease responsible for the 
cleavage and subsequent decrease of TRIF and IPS-1 during CVB3 infection, lysates 
derived from HeLa cells was incubated with 2Apro active recombinant protease. Western 
blot analysis of these lysates detected similar sized cleavage fragments as those observed in 
during CVB3 infection of HeLa cells (Figure 7). Suggesting that it is indeed 2Apro mediated 
cleavage, that is the underlying cause for TRIF and IPS-1 reduction during CVB3 infection. 
 
It has been shown that perturbation of interferon I production is due to 3Cpro mediated 
cleavage of IPS-1 and TRIF during CVB3 infection in HEK293 cells (140). Although, our 
observations are more in line with those made by Feng et al. 2014 (139) who also observed 
that IPS-1 degradation is 2Apro mediated. In EV71 infection, IPS-1 cleavage also seems to 
result from 2Apro, as shown by Wang et al. 2013 (197). The discrepancies between these 
studies could be due to multiple reasons, for instance differing time-points, cell lines and 
virus strains, or potential overlap between 2Apro and 3Cpro cleavage specificity. 
 
In paper I, we can conclude that CVBs target the innate signalling pathway and this is in 
part achieved by 2Apro mediated cleavage of IPS-1 and TRIF during CVB3 infection. This 
leads to a block in the expression of type III interferons, which in turn is likely to promote 
both the replication and spread of the virus in an infected host.  
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4.2 NEW COXSACKIEVIRUS 2APRO AND 3CPRO PROTEASE 
ANTIBODIES FOR VIRUS DETECTION AND DISCOVERY OF 
PATHOGENIC MECHANISMS (PAPER II) 
 
Epidemiological studies have suggested a link between type 1 diabetes (T1D) and 
enterovirus infections (reviewed in section 1.3.1). Many of these studies relied on 
immunohistochemistry (IHC) staining of pancreatic tissue from T1D organ donors using an 
antibody directed against the enteroviral capsid protein VP1 (clone 5D8/1, Dako). Concerns 
have been raised that this widely used antibody may have cross-reactivity with two 
endogenous cellular proteins, namely a creatine kinase and mitochondrial ATP synthase 
(124). Further characterisations have shown that this VP1 antibody binds to a linearized 
epitope consisting of a conserved sequence that is present in many enteroviruses, but may 
also occur in host proteins (198). As such, we identified the need for new tools for use in 
detecting enteroviruses in serum and tissue samples and for reagents that could be used in 
furthering our understanding of enterovirus biology. We developed three new monoclonal 
antibodies directed against the enterovirus encoded proteases 2Apro and 3Cpro. 
 
Using the genetic sequence derived from CVB3 Nancy (UniProtKB/Swiss-Prot: P03313.4), 
his-tagged 2Apro and 3Cpro were cloned into bacterial expression vectors and recombinant 
his-tagged protein was produced in E. coli and purified. Recombinant proteins were used to 
immunise Wistar rats (199) and to generate hybridomas for monoclonal antibody 
production. The clones were selected based on their detection of CVB3 in infected HeLa 
cell lysates by wb and through their reactivity in IHC when screening pancreas derived 
from CVB3 infected mice. Two clones for 2Apro denoted as 2A-1 and 2A-2 and one for 
3Cpro denoted 3C were identified and selected for large-scale antibody production. 
 
The earliest time point that the proteases were detected was at 4 hours post infection (hpi) 
and their expression remained stable until cell lysis occurred at 9 hpi (Figure 1C). Time-
course experiment showed that 2Apro and 3Cpro expression kinetics mirrored those of the 
capsid protein VP1. In western blot both 2Apro (2A-I) and 3Cpro (3C) antibodies were able 
to detect all six of the different CVB serotypes (CVB1-6; Figure 1D) in HeLa cells 6 hpi. 
Analysis of CVB3 infected HeLa cells by flow cytometry confirmed the efficacy of the 
antibodies for detection of viral proteases with an orthologous methodology (Figure 3A-C), 
and once again, staining for the proteases was in concordance with that for VP1 expression.   
 
When the antibodies were employed in IHC using a cell array containing cells infected with 
virus species from enterovirus group EV-A and EV-B, both 2A-II and 3C were able to 
detect the proteases of all species that belong to the EV-B but not EV-A (Table 1). The only 
exception to this was 2A-2 which showed no staining for Echovirus 9 (an EV-B virus) in 
infected cells. Moreover, excellent specificity of the antibodies for the EV-B species was 
demonstrated as the new 2Apro and 3Cpro antibodies did not detect any viruses belonging to 
the enterovirus A group. When the antibodies were used to probe pancreas tissue from 
CVB3 or CVB5 infected NOD mice, it was possible to confirm expression of the viral 
proteases on days 3 and 5 post infection (dpi) (Figure 2).  
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Translocation of cellular proteins from the nucleolus to the cytoplasm during infection with 
CVBs is known to occur during infection (reviewed in chapter 1.3.2). Also viral proteins 
have been known to enter the cell nucleus, localisation of 3Cpro has previously been 
described (200, 201), although the protease itself lacks the required nuclear localisation 
signal (NLS). However in poliovirus, rhinovirus and FMDV, the viral RNA polymerase 3D 
harbours such a signal (202–204). It has been suggested that during infection 3Cpro localises 
to the nucleus as a fusion protein (3CD), but that this process is dependent on the activity of 
2Apro (205). Confocal microscopy analysis of time course infections of HeLa cells with 
CVB3, using the 2Apro and 3Cpro revealed robust expression of the viral proteases at 4 hpi 
(Figure 4A-E). In our cell system, nuclear localisation of either of the viral proteases was 
negligible between 2-6 hpi. This raises the question of whether such a nuclear localisation 
of 3Cpro occurs during CVB3 infection. More detailed examination of this is required, 
although it should be noted that a NLS sequence in CVB3 3D has not been reported.  
 
To summarise, paper II describes the development of 2Apro and 3Cpro specific antibodies. 
The antibodies generated can be used in different applications for the detection of EV-B 
species and will be of value when examining infection kinetics or cross-validating other 
detection methodologies. 
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4.3 COXSACKIEVIRUS AFFECTS MULTIPLE STEPS IN INSULIN 
SECRETION PATHWAY LEADING TO IMPAIRED INSULIN 
RELEASE BY INFECTED BETA CELLS (PAPER III) 
 
Enteroviruses have been found in the pancreatic islets of patients with T1D, suggesting that 
direct infection of the β-cells might contribute to diabetes development. This hypothesis is 
supported by in vitro studies demonstrating that β-cells infected with CVBs have 
impairments in glucose stimulated insulin release (206, 207). 
 
The virus encoded proteases 2Apro and 3Cpro are known to cleave an extensive range of host 
proteins during infection (93).  In paper III we wanted to explore the hypothesis that β-cell 
dysfunction observed during CVB infection is due to the expression of 2Apro and 3Cpro. 
Additionally, we also wanted to determine whether the expression of the non-structural 
protein 3A has an effect on β-cells, as this viral protein has previously been reported to 
block the secretion of the cytokines IL-6 and IL-8 (208) . 
 
We first infected human pancreatic islets with CVB3 or CVB4, and validated that the CVBs 
replicate successfully in islets and increased in number through monitoring the release of 
infectious virions in the islet culture media at 48 hpi (Figure 1A). Upon glucose challenge, 
infected islets showed a trend towards a reduced GSIS (Figure 1B). Under the same 
experimental conditions islets were also evaluated for their insulin content (Figure 1C), and 
insulin mRNA expression (Figure 1D), however no statistically significant decreases in 
insulin mRNA or content were observed. These results supported the conclusion that 
lowered insulin responses upon glucose challenge were due to a defect in insulin secretion 
rather than alterations in the production of insulin during infection.  
 
Next, we wanted to reproduce these findings in a pancreatic β-cell line of rat origin (INS-1-
832/13 cells), which supports CVB replication (209). Several studies have also 
demonstrated that INS-1-832/13 cells are a valid cell system for studying insulin secretion 
(172). Optimisation experiments examining suitable time-points and multiplicity of 
infection (MOIs) were conducted, GSIS was then conducted at 5 hpi after infecting cells 
with CVB4 at 100 MOI. Similar to the previous observations in infected islets, INS1-
832/13 cells displayed a trend towards reduced glucose stimulated insulin secretion 
following infection with CVB4 (Figure 2C). We were also able to validate the presence of 
the non-structural proteins 2Apro, 3Cpro and 3A by PCR or western blot, in samples used in 
the insulin secretion experiments (Figures 3B and 3C), confirming their expression under 
our experimental conditions.  
 
To further investigate the effect that the non-structural proteins exerted on β-cell function, 
2Apro, 3Cpro and 3A derived from the CVB3 sequence were cloned into vectors and used in 
transfection experiments in INS1-832/13 cells. Initially, low transfection efficiencies of 
INS1-832/13 cells were observed. Therefore to evaluate the effect of the expression of non-
structural proteins on glucose stimulated hormone release, a modified transfection protocol 
was adopted. In cells overexpressing human growth hormone (hGH), hGH is localised in 
the same vesicles as insulin and as such, these cells co-secrete hGH with insulin upon 
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glucose challenge (178, 210). Thus, by co-transfecting hGH constructs with constructs 
encoding the viral non-structural proteins, hGH can be measured as a proxy for insulin 
secretion. This experimental design provided a platform to evaluate the effect that the 
ectopic expression of non-structural viral proteins has on β-cell function, despite low 
transfection efficiency in INS1-832/13 cells through selectively evaluating cells that have 
been successfully transfected with both constructs. The viral proteases are known to affect 
both translation and transcription of host cell mRNA (92, 211), and this was also evident in 
our experiments as well. The level of hGH was undetectable in 2Apro co-transfected INS1-
832/13 cells and reduced in those expressing 3Cpro. In contrast cells expressing 3A had 
higher levels of hGH (Figure 4C). As a result of this, changes in glucose stimulated insulin 
secretion could only be evaluated in 3Cpro and 3A transfected cells and overall, the changes 
in secretory capacity were not significantly different for either protein (Figure 4D), 
although there was a trend towards a reduction in the fold change differences between basal 
and glucose stimulated hGH secretion for both. 
 
Monitoring of cell capacitance during patch clamp after depolarising the cell with a train of 
ten 500-ms fluctuations between 0 to -70mV allows for the degree of exocytosis to be 
estimated. For all three non-structural proteins (2Apro, 3Cpro and 3A) a significant reduction 
in membrane capacitance was be recorded (Figures 5B, D, F). By using an independent 
method for measuring exocytosis, namely total internal reflection fluorescence (TIRF) 
microscopy, it was possible to confirm the observations made in the patch clamp 
experiments. Results showed the expression of 2Apro, 3Cpro and 3A had a clear negative 
impact on exocytosis (Figure 6C, D, F, G), while granular density of docked vesicles at 
plasma membrane was only slightly less for 2Apro as compared to control (Figure 6E and 
H). Together this suggest that the negative effect exerted by viral proteins occur at a late 
stage of exocytosis.  
 
The process of exocytosis is driven by an influx of extracellular calcium (Ca2+) into the cell 
through voltage-gated calcium channels (212). Therefore, calcium currents were measured 
by patch clamp in transfected INS1-832/13 cells. Expression of either of the proteases 
decreased the Ca2+ currents while 3A did not have the same effect (7A-C), possibly 
indicating modulation of the voltage gated Ca2+ channels at the plasma membrane or some 
process regulating Ca2 flux.  
 
The results presented in paper III, support the previous observations that CVB infection 
causes β-cell dysfunction in vitro and that infection negatively impacts the cells capacity to 
secrete insulin upon glucose stimulation. Through using different methodologies aimed at 
evaluating exocytosis in β-cells (patch clamp, TIRF microscopy, hGH secretion assay), we 
demonstrate that the overexpression of CVB3 non-structural proteins 2Apro, 3Cpro and 3A in 
INS1-832/13 cells inhibits different aspects of insulin secretion in beta cells. As such, viral 
non-structural proteins could contribute to the β-cell dysfunction observed during CVB 
infection. 
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4.4 COXSACKIE B VIRUS PROTINASE SUBSTRATE REPERTOIRE 
DEFINED IN HUMAN PROTEOME BY N-TERMINAL 
PROTEOMICS UNCOVERS CLEAVAGE OF TCF7L2 BY 2APRO 
(PAPER IV) 
 
 
Endogenous proteases regulate many processes within the cell by cleaving host proteins 
leading to alterations in their function, rewiring of protein-protein interactions or shifts in 
subcellular localisation. Aside from processing the viral polyprotein, the viral proteases 
2Apro and 3Cpro have essential roles in modulating the host cell to favour virus replication 
and spread.  
 
To understand enterovirus biology and to find a mechanistic explanation for the observed 
phenotype of β-cells transfected with 2Apro and 3Cpro (paper III) we wanted to define the 
specific substrate repertoire of the viral proteases. The methodology chosen for this study 
known as subtiligase labelling (discussed in chapter 1.1.7) (15, 67). Two distinct sample 
types were used; protein lysates derived from CVB3 (EGFP tagged) infected cells (forward 
experiment) and protein lysates incubated with recombinant 2Apro/3Cpro or catalytically 
inactive mutants (reverse experiment) (Figure 2).  The following cell lines, HeLa, CaCo-2, 
EndoC-βH1 (Table 1) were included in the study in order to cover a wide range of potential 
substrates, as CVB infection kinetics and the abundance of individual proteins might vary 
between cell lines.  
 
First, the suitability of the samples was validated. Infected cells all had robust replication of 
CVB3 at 4-6 hpi (Figure 2A, B). The cleavage of the previously defined CVB substrates 
MAVS (2Apro (139, 141)) and G3BP1 (3Cpro (213)) were observed under experimental 
conditions (Figure 2C). This provided us with confidence that the chosen experimental 
conditions were suitable for detecting substrate cleavage with the subtiligase labelling 
method. Indeed, analysis of LC-MS/MS raw data and subsequent data cleaning provided us 
with a number of unique peptides in each data set that were derived from proteolytically 
processed proteins. Due to the low number of replicates (three) for each sample type and 
cell line we decided to combine all of the peptides detected in each sample type (grouping 
data from all cell lines). Then by overlapping the data sets between the forward and reverse 
experiments we were able to validate a number of substrates that are cleaved both during 
infection and in lysates digested with recombinant 2Apro or 3Cpro (Figure 3A). The proteins 
that overlapped between the forward and reverse experiments are subsequently referred to 
as validated substrates. Detected peptides matched the cleavage specificity of the viral 
proteases as defined by the cleavage positions in the viral polyprotein (Figure 3B). This 
gave us confidence that the peptides detected were indeed derived from viral protease 
substrates and not generated by endogenous cellular proteases.  
 
The validated substrates numbered 81 proteins in total (Figure 4) and the majority of 
substrate cleavage sites could be assigned to either 2Apro or 3Cpro, although there were 
seven exceptions where the cut positions were found to be overlapping between both 
proteases (Figure 3A). In addition, some proteins also have multiple cut sites belonging to 
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the same viral protease, examples of which include AGFG1, CBX8, CEP170, CSTF2 and 
TAF15. If these substrates with multiple cut sites carry greater significance when compared 
to those with single cut site, warrants further investigation. 
 
Pathway analysis of the validated substrates showed statistically significant enrichment for 
multiple biological pathways (Figure 5). Pathways relating to RNA metabolism and 
SUMOylation of RNA binding proteins contained the largest number of substrates. The 
interplay between enterovirus replication and cellular RNA metabolism or SUMOlaytion 
has been described earlier (160, 214–217). However, the majority of substrates uncovered 
in this study, that belong to the enriched pathways, have not been identified previously. The 
detailed description of the functional impact of these cleavage events will further refine our 
understanding of how enterovirus replication modulates cellular RNA metabolism and 
SUMOylation. The repression of WNT target gene pathway was also enriched, as 
represented by the proteins transducin like enhancer of split 3 (TLE3) and transcription 
factor 7 like 2 (TCF7L2). This pathway was of interest to us as mounting evidence suggest 
that Wnt signalling modulates normal b-cell function (218), especially as genetic variants 
of the transcription factor TCF7L2 have been linked to type 2 diabetes development (219–
221). Moreover, an essential role for TCFL2 has also been demonstrated for the 
maintenance of the glucose stimulated secretory capacity of b-cells (222, 223). 
 
To further explore possible disease associations among the validated substrates, our data 
was cross referenced with the disease association database DisGenNET (189). Of the 17 
proteins present in the database there were an association with 24 different diseases, with 
some substrates being associated to multiple conditions. TCF7L2 was associated with 
diabetes mellitus (non-insulin dependent) with confidence score of (0.38; Figure 6). 
Interestingly, a diverse array of diseases are represented among the substrate several that 
have hallmarks of neuronal diseases, amyotrophic lateral sclerosis (ALS ((224)), 
spinocerebellar ataxia type 2 (SCA2 ((225)), infection-induced acute encephalopathy 3 
(IIAE3 ((226)) and these findings are worthy of note as enterovirus infections are known to 
cause various neurological complications (227–229). If these substrates are in some way 
important for maintaining normal neuronal function or if cleaved, might contribute to 
neuronal pathology remains to be explored. 
 
By definition essential proteins are crucial for maintaining the proper function of the 
cellular machinery. If such a protein in compromised, this could severely affect the viability 
of the cell. In evaluating the impact of a proteolytic cleavage for the phenotype of a cell, 
identifying essential proteins among the validated substrates is important. An estimate of 
essentiality can be made based on a protein location (centrality; (230) within a protein-
protein interaction network (interactome). In order, to identify essential proteins, a human 
interactome was built using the IntAct database (190), and each substrate was mapped to 
this network and the betweenness centrality measured (Supplementary 1; (231). Ranking of 
substrates based on centrality indicated that TCF7L2 was among the substrates that scored 
above the 90th percentile, and is thus likely to be a relatively essential protein. 
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Additionally, when measuring the distance between validated substrates, it became evident 
that the average distance between validated substrates was significantly shorter compared to 
the control substrates (Supplementary 3). In reviewing the nearest neighbours within the 
network, many of the validated substrates were direct interaction partners (Supplementary 
2), supporting the idea that proteolysis by the viral proteases is targeted in the human 
interactome. 
 
Since there is substantial evidence in the scientific literature describing the importance of 
TCF7L2 for b-cell function and the likelihood that it is an essential protein based on its 
betweenness centrality score, we wished to validate its cleavage by an independent 
methodology. Samples used in subtiligase labelling experiments (HeLa and EndoC-βH1) 
were analysed by western blot and TCF7L2 was detected. Full-length protein disappeared 
and potential cleavage products appeared upon CVB3 infection and after protein lysates 
were incubated with recombinant 2Apro (Figure 7A). In control samples or those incubated 
with catalytically inactive proteases, full-length TCF7L2 remained intact and no cleavage 
products were observed indicating that TCF7L2 is exclusively cleaved by 2Apro. 
 
Based on the peptide detected by mass spectrometry the amino acid position of the 
proteolytic cleavage could be determined and was found to occur between threonine (T) 
and glycine (G) at position 308 (Supplementary 5B). Wild type (wt) TCF7L2 and cleavage 
resistant mutants in which glycine had been changed to alanine (A) or glutamic acid (E) at 
position 308, were stably expressed in HeLa cells by lentivirus transduction. In each 
TCF7L2 construct a V5-tag at the N-terminus and HA-tag in the C-terminus were 
introduced. Upon infection with CVB3, each of the terminally labelled smaller cleavage 
fragments of wt TCF7L2 could be detected, while mutants G308A and G308E were 
resistant to proteolytic processing (Figure 7B). This confirmed that the 308 position is 
indeed the site cleaved by the protease. Overexpression of each individual cleavage 
fragment also indicated that degradation of the N-terminal cleavage fragment occurs during 
CVB3 infection while the C-terminal fragment remains stable. It is possible that the C-
terminal fragment can impact virus replication or cellular function, although this needs to 
be tested experimentally.  
 
In summary, paper IV is an exploration of the viral protease substrate repertoire where 81 
high confidence substrates targeted by 2Apro / 3Cpro during CVB3 infection were identified. 
A combination of pathway and network analysis revealed enrichment of validated 
substrates in different biological pathways with multiple proteins in close proximity to each 
other within pathways. Integration of a database containing disease associated genes 
highlighted TCF7L2 as a target of interest due to its role in maintaining normal b-cell 
function. Moreover, we validated TCF7L2 as a bona fide 2Apro substrate. To our knowledge 
this is the most extensive survey to date of the CVB3, 2Apro and 3Cpro substrate repertoire. 
Future studies will focus on defining the relevance of proteolytic cleavage both for virus 
replication and for the host cell. 
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5 CONCLUDING REMARKS 
 
This thesis has focused on exploring the biology of enteroviruses and more specifically the 
virally encoded proteases 2Apro and 3Cpro, first and foremost by defining the host cellular 
proteins that are targeted by the viral proteases during infection. By doing this, we are 
furthering our knowledge regarding the types of cellular functions that these viruses have 
evolved to modulate, and this will allow us to start exploring the phenotypic relevance of 
these cleavage events for both the virus and the host cell. Hopefully some of these 
observations may provide insights into the pathological processes or diseases that are 
caused by or associated with enterovirus infections. 
 
In writing this thesis, articles have been cited that span more than 50 years of research. In 
surveying this scientific literature, it becomes evident that enteroviruses will continue to be 
of importance to human health both in the near and distant futures. The disease burden 
attributed to acute and chronic infections is substantial and there is a need for the 
development of curative and preventive therapies. Success stories regarding the treatment 
of a diverse number of diseases, such as those caused by human immunodeficiency virus 
(HIV), hepatitis C virus (HCV) and human papillomavirus (HPV) teaches us that 
understanding basic molecular virology is essential for attaining efficient treatments.  
 
The American novelist Paul Auster once wrote, “The truth of the story lies in the details”, 
which is at the heart of a scientist’s purpose, namely to uncover new details. It is my hope 
that the results presented here will contribute to the collection of details related to the 
ongoing story of enterovirus biology, allowing us one day to discover the true nature of 
these fascinating viruses. 
 
Based on the original research articles and manuscripts presented in this thesis, the 
following findings have been made:  
 
Paper I, describes how CVBs are capable of blocking the type III interferon response 
during infection by the activity of a viral encoded protease.  
 
Paper II, discusses the development of 2Apro and 3Cpro antibodies, which are highly 
specific for viruses belonging to EV-B species. 
 
Paper III, investigates the impact of CVB infection on the capacity of b-cell to undergo 
glucose stimulated insulin release. Showing that some of the negative impact on exocytosis 
might be due to the expression of the viral non-structural proteins 2Apro, 3Cpro and 3A 
during infection. 
 
Paper IV, is a comprehensive survey of the 2Apro and 3Cpro substrate repertoire, identifying 
81 substrates and further validating the protein TCF7L2 as a 2Apro substrate. This work 
provides a potential mechanistic explanation for b-cell dysfunction observed during CVB 
infection. 
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